ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,077,000 | +306.4% | 44,485 | +797.1% | 0.00% | +100.0% |
| Q4 2020 | $265,000 | -65.9% | 4,959 | -82.9% | 0.00% | -80.0% |
| Q1 2019 | $776,000 | +288.0% | 29,043 | +199.8% | 0.01% | +400.0% |
| Q3 2018 | $200,000 | -42.7% | 9,687 | -38.3% | 0.00% | -66.7% |
| Q1 2018 | $349,000 | -23.6% | 15,695 | -0.8% | 0.00% | -25.0% |
| Q4 2017 | $457,000 | +0.2% | 15,815 | +31.2% | 0.00% | 0.0% |
| Q3 2017 | $456,000 | +38.2% | 12,058 | +2.0% | 0.00% | +33.3% |
| Q2 2017 | $330,000 | -8.6% | 11,821 | +5.8% | 0.00% | 0.0% |
| Q1 2017 | $361,000 | +35.7% | 11,171 | +8.5% | 0.00% | 0.0% |
| Q4 2016 | $266,000 | +8.6% | 10,296 | +33.8% | 0.00% | 0.0% |
| Q3 2016 | $245,000 | +17.8% | 7,697 | +18.5% | 0.00% | 0.0% |
| Q2 2016 | $208,000 | -43.6% | 6,497 | -2.4% | 0.00% | +200.0% |
| Q1 2016 | $369,000 | +81.8% | 6,660 | +6.8% | 0.00% | -66.7% |
| Q1 2015 | $203,000 | – | 6,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |